Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | ACHE | P22303 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.50 |
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1205432 | 0.81 | CHRM4 (0.52) | SMN1; SMN2RECQLACHEKDM4EALDH1A1 | |
| SCHEMBL16681129 | 0.79 | CPN1 (0.45) | SMN1; SMN2KDM4EALDH1A1OPRM1 | |
| SCHEMBL3314251 | 0.79 | SMN1; SMN2 (0.54) | SMN1; SMN2RECQLACHEKDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL1461761 | 0.78 | SMN1; SMN2 (0.53) | SMN1; SMN2RECQLACHEKDM4EALDH1A1 | |
| SCHEMBL2085351 | 0.77 | NPC1 (0.61) | SMN1; SMN2RECQLACHEALDH1A1DRD2 | |
| SCHEMBL3959065 | 0.76 | ACHE (0.66) | SMN1; SMN2RECQLACHEKDM4EALDH1A1 | |
| SCHEMBL2085442 | 0.76 | SMN1; SMN2 (0.56) | SMN1; SMN2RECQLACHEDRD2DRD4 | |
| SCHEMBL3709310 | 0.76 | RECQL (0.70) | SMN1; SMN2RECQLACHEKDM4EALDH1A1 | |
| SCHEMBL2088709 | 0.76 | KDM4E (0.58) | SMN1; SMN2RECQLACHEKDM4EALDH1A1 | |
| SCHEMBL1016673 | 0.76 | ABL1 (0.47) | ACHEABL1RIN1OPRM1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110034444-A1 | SELECTED CGRP ANTAGONISTS, PROCESSES FOR PREPARING THEM AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-10 | — | — | US | disclosed |
| US-7858622-B2 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-28 | — | — | US | disclosed |
| US-20100004228-A1 | SELECTED CGRP ANTAGONISTS, PROCESSES FOR PREPARING THEM AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-07 | — | — | US | disclosed |
| US-7579341-B2 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-08-25 | — | — | US | disclosed |
| US-20070049581-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004228-A1 | SELECTED CGRP ANTAGONISTS, PROCESSES FOR PREPARING THEM AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | CALCRL, CALCR, CALCA | SMN1; SMN2 4312/4885RECQL 383/4885ACHE 811/4885 |
| US-20070049581-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | SMN1; SMN2 4312/4885RECQL 383/4885ACHE 811/4885 |
| US-20110034444-A1 | SELECTED CGRP ANTAGONISTS, PROCESSES FOR PREPARING THEM AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | CALCRL, CALCR, CALCA | SMN1; SMN2 4312/4885RECQL 383/4885ACHE 811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.